Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, announced inducement grants to seven new employees between August 4-18, 2025. The grants include 6,959,013 stock options and 1,491,217 restricted stock units (RSUs).
The stock options have exercise prices of $2.04-$2.11 per share with a ten-year term. Both options and RSUs follow a four-year vesting schedule, with 25% vesting after 12 months, followed by monthly vesting for options and quarterly vesting for RSUs over the next 36 months. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Vor Bio (Nasdaq: VOR), una biotech in fase clinica, ha annunciato concessioni incentivanti a sette nuovi dipendenti tra il 4 e il 18 agosto 2025. Gli incentivi comprendono 6.959.013 opzioni su azioni e 1.491.217 unit脿 di azioni vincolate (RSU).
Le opzioni hanno un prezzo di esercizio di $2,04鈥�$2,11 per azione e durata decennale. Opzioni e RSU seguono un piano di maturazione quadriennale: il 25% matura dopo 12 mesi, quindi le opzioni maturano mensilmente e le RSU trimestralmente nei successivi 36 mesi. Queste assegnazioni sono state effettuate ai sensi del Vor Biopharma Inc. 2023 Inducement Plan, in conformit脿 con la Nasdaq Listing Rule 5635(c)(4).
Vor Bio (Nasdaq: VOR), una biotecnol贸gica en fase cl铆nica, anunci贸 concesiones por incentivo a siete nuevos empleados entre el 4 y el 18 de agosto de 2025. Las concesiones incluyen 6.959.013 opciones sobre acciones y 1.491.217 unidades restringidas de acciones (RSU).
Las opciones tienen precios de ejercicio de $2,04鈥�$2,11 por acci贸n y un plazo de diez a帽os. Tanto las opciones como las RSU se rigen por un calendario de consolidaci贸n de cuatro a帽os: el 25% se consolida tras 12 meses, y a continuaci贸n las opciones se consolidan mensualmente y las RSU trimestralmente durante los siguientes 36 meses. Estas concesiones se otorgaron bajo el Vor Biopharma Inc. 2023 Inducement Plan, en cumplimiento de la Nasdaq Listing Rule 5635(c)(4).
Vor Bio (Nasdaq: VOR), 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤 須岇偓臧� 2025雲� 8鞗� 4鞚茧秬韯� 18鞚� 靷澊鞐� 7氇呾潣 鞁犼窚 歆侅洂鞐愱矊 鞚胳劶韹半笇 攵�鞐ゼ 氚滍憸頄堨姷雼堧嫟. 攵�鞐悳 鞚胳劶韹半笇電� 6,959,013欤� 欤检嫕毵れ垬靹犿儩甓�瓿� 1,491,217欤检潣 鞝滍暅攵�欤检嫕雼渼(RSU)鞛呺媹雼�.
欤检嫕毵れ垬靹犿儩甓岇潣 頄夓偓臧�瓴╈潃 欤茧嫻 $2.04鈥�$2.11鞚措┌ 鞙犿毃旮瓣皠鞚� 10雲勳瀰雼堧嫟. 鞓奠厴瓿� RSU電� 氇憪 4雲勳潣 氩犾姢韺� 鞚检爼鞚� 鞝侅毄霅橂┌, 12臧滌洈 頉� 25%臧� 氩犾姢韸鸽悩瓿� 鞚错泟 36臧滌洈 霃欖晥 鞓奠厴鞚� 毵れ洈, RSU電� 毵る秳旮� 氩犾姢韺呺惄雼堧嫟. 鞚� 攵�鞐姅 Vor Biopharma Inc. 2023 Inducement Plan鞐� 霐半澕 鞚措（鞏挫鞙茧┌ Nasdaq Listing Rule 5635(c)(4)毳� 欷�靾橅暕雼堧嫟.
Vor Bio (Nasdaq: VOR), une soci茅t茅 biotechnologique en phase clinique, a annonc茅 des attributions incitatives 脿 sept nouveaux employ茅s entre le 4 et le 18 ao没t 2025. Les attributions comprennent 6 959 013 options d'achat d'actions et 1 491 217 unit茅s d'actions restreintes (RSU).
Les options ont des prix d'exercice de $2,04鈥�$2,11 par action et une dur茅e de dix ans. Les options et les RSU suivent un calendrier d'acquisition sur quatre ans : 25 % acquis apr猫s 12 mois, puis acquisition mensuelle pour les options et trimestrielle pour les RSU au cours des 36 mois suivants. Ces attributions ont 茅t茅 effectu茅es dans le cadre du Vor Biopharma Inc. 2023 Inducement Plan, en conformit茅 avec la Nasdaq Listing Rule 5635(c)(4).
Vor Bio (Nasdaq: VOR), ein Biotech-Unternehmen in klinischer Phase, gab Zuteilungen als Anreiz an sieben neue Mitarbeiter zwischen dem 4. und 18. August 2025 bekannt. Die Zuteilungen umfassen 6.959.013 Aktienoptionen und 1.491.217 Restricted Stock Units (RSU).
Die Aktienoptionen haben Aus眉bungspreise von $2,04鈥�$2,11 pro Aktie und eine Laufzeit von zehn Jahren. Sowohl Optionen als auch RSUs folgen einem vierj盲hrigen Vesting-Zeitplan: 25 % vesten nach 12 Monaten, anschlie脽end vesten die Optionen monatlich und die RSUs viertelj盲hrlich 眉ber die folgenden 36 Monate. Diese Zuteilungen erfolgten im Rahmen des Vor Biopharma Inc. 2023 Inducement Plan und entsprechen der Nasdaq Listing Rule 5635(c)(4).
- Significant equity incentives to attract new talent
- Structured vesting schedule promotes employee retention
- Potential dilution for existing shareholders from nearly 8.5 million new shares
CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio鈥檚 common stock and restricted stock units (鈥淩SUs鈥�) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio鈥檚 common stock to seven newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the 鈥淚nducement Plan鈥�).聽 聽 聽 聽聽
The stock options have a ten-year term and exercise prices ranging from
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Media & Investor Contacts:
颁补谤濒听惭补耻肠丑
Sarah Spencer
FAQ
How many shares were granted in Vor Bio's (VOR) August 2025 inducement grants?
What is the vesting schedule for Vor Bio's (VOR) August 2025 inducement grants?
What is the exercise price for Vor Bio's (VOR) August 2025 stock options?
How many employees received Vor Bio's (VOR) August 2025 inducement grants?
